Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes

Post author:Trudy Horsting
Post published:November 8, 2019
Post category:Congenital myasthenic syndromes Myasthenia Gravis

Firdapse, or amifampridine phosphate, is a medication currently approved for Lambert-Eaton myasthenic syndrome, or LEMS. However, Catalyst Pharmaceuticals has been working to evaluate if it can aid other neurological and…

Get Involved

This Men's Health Awareness month, share your authentic story with others. Raise awareness and inspire change!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Get Involved

Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More